School of Public Health, College of Public Health, Taipei Medical University, Taipei 110, Taiwan.
Department of Public Health, College of Public Health, China Medical University, Taichung 404, Taiwan.
Viruses. 2021 Apr 28;13(5):790. doi: 10.3390/v13050790.
Studies evaluating the association between age-related macular degeneration (AMD) risk and HCV infection are scant. In this population-based cohort study, 13,300 patients newly diagnosed as having HCV (HCV cohort) and 26,600 propensity score-matched patients without HCV (non-HCV cohort) were identified from the Taiwan National Health Insurance Research Database between 2000 and 2013. Furthermore, 1,983 patients with HCV who received pegylated interferon and ribavirin treatment (HCV-treated cohort) and propensity score-matched patients with HCV (matched at a ratio of 1:2) who did not receive this treatment (HCV-untreated cohort) were selected from the HCV cohort. Cox proportional hazards regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) associated with the risk of AMD in the HCV and non-HCV cohorts. The adjusted HR (aHR) for AMD in the HCV cohort was 1.22 (95% CI = 1.09-1.35). This significant association was observed only for nonexudative AMD (aHR = 1.22, 95% CI = 1.09-1.37). Compared with the HCV-untreated cohort, the HCV-treated cohort showed no significant association with any type of AMD (aHR = 1.07, 95% CI = 0.81-1.43). Age and sex did not modify AMD development after the exposure and treatment of chronic HCV infection. Our findings revealed that patients with chronic HCV infection had an increased risk of AMD.
评估年龄相关性黄斑变性（AMD）风险与丙型肝炎病毒（HCV）感染之间关系的研究较少。在这项基于人群的队列研究中，我们从 2000 年至 2013 年的台湾全民健康保险研究数据库中确定了 13300 例新诊断为 HCV 的患者（HCV 队列）和 26600 例匹配的无 HCV 的患者（非 HCV 队列）。此外，我们从 HCV 队列中选择了 1983 例接受聚乙二醇干扰素和利巴韦林治疗的 HCV 患者（HCV 治疗队列）和匹配的 HCV 患者（以 1:2 的比例匹配），这些患者未接受这种治疗（HCV 未治疗队列）。我们使用 Cox 比例风险回归模型计算了 HCV 和非 HCV 队列中 AMD 风险的风险比（HR）和 95%置信区间（CI）。HCV 队列中 AMD 的调整后 HR（aHR）为 1.22（95%CI=1.09-1.35）。这种显著关联仅见于非渗出性 AMD（aHR=1.22，95%CI=1.09-1.37）。与 HCV 未治疗队列相比，HCV 治疗队列与任何类型的 AMD 均无显著关联（aHR=1.07，95%CI=0.81-1.43）。年龄和性别并未改变慢性 HCV 感染后 AMD 的发生和治疗。我们的研究结果表明，慢性 HCV 感染患者患 AMD 的风险增加。
